



**Thursday, September 10, 2015**  
**7:00 a.m. to 8:30 a.m.**  
**Cannon Health Building**  
**Room 125**

**Board Members Present:**

**Tony Dalpiaz, PharmD.**  
**Susan Siegfroid, M.D**  
**Keith Tolman, M.D.**  
**Mark Balk, PharmD.**

**Jennifer Brinton, MD**  
**Jay Aldus, DDS**  
**Mr. Kumar Shah**  
**Michael Symond, M.D.**

**Board Members Excused:**

**Dept. of Health/Div. of Health Care Financing Staff Present:**

**Robyn Seely, Pharm.D**  
**Trevor Smith C.Ph.T.**  
**Merelynn Berrett, R.N.**  
**Heather Santacruz, R.N .**

**Chad Hope, Pharm.D.**  
**Bryan Larson, Pharm.D.**  
**Alyssa Pitts, R.N.**

**Other Individuals Present:**

**Joanita Lake, UofU**  
**Gary Oderda, UofU**  
**David Young, UofU**  
**Don McCaffrey, Vertex**  
**Holly Carveth, UofU**  
**Ted Liou, UofU**  
**Lisa Borland, Vertex**  
**Corinne Glock, Relypsa**  
**Lynda Roe, UofU**

**Jeff Zobell, IHC**  
**Charissa Anne, J&J**  
**Jeff Cameron, Dyax**  
**Tracey Meeks, Vertex**  
**Lori Howarth, Bayer**  
**Vidya Pugachenthi, UofU**  
**Gregg Rasmussen, Vertex**  
**Cody Ball, Select Health**  
**Mark Germann, Norvartis**

---

**Meeting conducted by: Tony Dalpiaz, Pharm.D.**

---

- 1. Welcome** – Tony Dalpiaz opened the meeting.
- 2. Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She also expressed appreciation for Tony Dalpiaz and Mark Balk for the time they have served on the DUR board. Kumar Shah has agreed to serve another year on the DUR board.
- 3. P&T Committee report** – The next P&T meeting will discuss agents used to Treat Irritable Bowel Syndrome (IBS) and Bowel Cleansing/Prep Agents.
- 4. Approval of prior meeting minutes** – Mark Balk made a motion, pending the correction

of a typing error, to approve the July meeting minutes. Keith Tolman seconded the motion. All in favor.

**5. RA treatments – 9 month review** – Robyn Seely said that the PA set last year on the RA treatments is working well and sees no problem with keeping the same criteria for this next year.

**6. Cystic Fibrosis Transmembrane Regulator Agents (Orkambi & Kalydeco)** – Joanita Lake, from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about the cystic fibrosis agents. Data was also presented about the utilization of the drugs in the Utah Medicaid population.

## **7. Public Comment**

- a. Theodore Liou, MD, (UofU) – He presented information on the cystic fibrosis agents and the benefits of the products in the treatment of his patients. He offered to answer board questions.
- b. Letter from Cystic Fibrosis Foundation – Read by Robyn Seely
- c. Lisa Borland (Vertex) – She presented information on Kalydeco and Orkambi. She requested that Utah Medicaid patients have access to the drugs and offered to answer any questions from the board.

## **8. Board Discussion - Cystic Fibrosis Transmembrane Regulator Agents**

- a. Jennifer Brinton said that these drugs are great in the way that they work, and while they are very expensive, they have the potential to keep children out of the hospital and avoid other costs.
- b. Mike Symond asked if the drugs would increase fertility in CF patients. He was answered that this has not been evaluated yet, because the drugs are new and long term outcome data has not been established.
- c. Jennifer Brinton asked if there is any chance to have Orkambi approved for patients under age 12. She was answered that there are current trials occurring, and more planned for the future for younger children.
- d. Keith Tolman asked what happens if a PA is requested for a child whose age is just outside the recommended guidelines. Robyn Seely answered that a DUR appeal will happen for those cases, which would be brought back before the board.
- e. Kumar Shah asked if there should be follow up requirements with the prescriber when using these drugs, and request notes on the patient progress.
- f. Mike Symond and Keith Tolman said that this should be the doctors responsibility, and if there are too many steps, patient care can be impacted negatively.
- g. Jennifer Brinton thinks that the proposed PA criteria is good as it follows label guidelines.
- h. Theodore Liou said that in his experience while treating CF patients, a problem can occur when patients aren't compliant and skip monthly treatments.
- i. Gary Oderda said that the DRRC can perform patient reviews to ensure patient

adherence to the medication, and work with the prescribers when needed.

- j. Jennifer Brinton made a motion to accept the PA criteria as written. Keith Tolman seconded the motion. All in favor.
- k. Mark Balk made a motion saying the the DRRC will review these CF drugs, and if compliance is not consistent, the prescriber will be contacted. Susan Siegfried seconded the motion. All in favor.

**9. Meeting Adjourned** – Mark Balk made a motion to close the meeting. Keith Tolman seconded the motion. All in favor.

The next DUR Board meeting is scheduled for Thursday, October 8<sup>th</sup>. Tentative schedule is to discuss Proprotein convertase subtilisin/kexin type 9 (PCSK9) agents.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)